Table 3.

Sites of disease, imaging results, trastuzumab therapy history, and follow-up

Patient	Sites of known disease*	Visualized sites 64Cu-trastuzumab	Sites of disease progression	Time to progression from initial 64Cu-trastuzumab injection (months)	Last follow-up since initial antibody (months)	Last trastuzumab treatment since initial antibody (months)
1	Liver+, bone+	Liver	Liver, bone lung	2.8, 7.2, 64.5	90.5	85
2	Lung, bone, brain	Negative	Brain, lung	12.2, 50.6	59.5	58
3	Liver, bone, mediastinum	Negative	Brain	51.6	85.3	85
4	Bone+	Negative	Bone	17.5	42.2	33
5	Bone+, liver−	Negative	Brain	8.2	62.7	38
6	Breast+, bone−	Negative	Breast 5.6m, adrenal 28.2m, liver 33.2m, brain 31m, skin 16.6m	5.6, 28.2, 33.2, 31, 16.6	36.1	35
7	Bone, brain, lung	Negative	Brain	1.4	1.6	2
8	Breast+	Breast	N/A	no progression	74	73
9	Bone+	Negative	Bone, liver, brain, abdominal node, and peritoneal carcinomatosis	4, 17, 23.6, 28.9, 28.9	35.1	34
10	Bone-na	Negative	NA	no progression	70	70
11	Bone-na	Negative	Brain	5.5	32.3	6

^*Note: “+” or “−” refers to patients who had FDG in addition to conventional imaging.